ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Pharmaceuticals

Fujifilm joins Gates Foundation coronavirus treatment initiative

Denmark subsidiary's facility to produce drug supplies for low-income countries

Fujifilm's logo: Currently, there are no established therapies for the treatment of COVID-19.    © AP

Tokyo -- Fujifilm Diosynth Biotechnologies is allocating manufacturing capacity at its Denmark facility to develop coronavirus treatments with the COVID-19 Therapeutics Accelerator led by the Bill and Melinda Gates Foundation.

Diosynth Biotechnologies is a subsidiary of Fujifilm Holdings, which also produces Avigan, the flu medication said to be effective in treating the novel coronavirus.

Under the agreement, the pharmaceutical manufacturer's facility in Hillerod, Denmark, will dedicate some of its resources to secure treatment supplies through 2021 for coronavirus patients in low-income countries.

"We are honored that Fujifilm Diosynth Biotechnologies is able to use its resources to support COVID-19 Therapeutics Accelerator partners in their mission to improve health," Martin Meeson, chief executive officer of Diosynth Biotechnologies, said in a press release.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more